Kintari’s product line now consists of four skincare products, all uniquely formulated utilizing our patented Invisicare® skin delivery technology and developed by scientists from Skinvisible Pharmaceuticals, Inc.

“Our customers have been asking for an effective moisturizer that both men and women can use to combat the effects of dry skin, flaking and scaling. We are pleased with the exceptional comments we have received about how great their skin feels when they use our new Hand & Body lotion,” said Mr. Terry Howlett, President of Kintari. “Our Invisicare skin delivery technology allows the ingredients to bind to the skin and provide long-lasting moisturization while providing an effective skin barrier that leaves the skin soft, supple and smooth. Additionally, we are pleased to announce that we surpassed the 1,000th order for Kintari this quarter and are seeing exponential growth as more and more distributors become part of our expanding team.”

Kintari’s Hand & Body lotion is formulated with five moisturizers including aloe, shea butter, glycerin, coconut oil and jojoba oil. Its main benefits include: smooth, satiny skin; helps to repair skin elasticity; provides nourishment to the skin and assists in preventing skin moisture loss. Kintari’s complete product line is available on www.kintari.com and through our independent distributors and their websites.

Kintari is a network marketing company with its products all powered by our patented Invisicare® technology. Our keystone products include our Youth Renewed Day and Night creams, which provide exceptional anti-aging solutions. In addition we offer our Skinbrella® broad spectrum SPF30 sunscreen; a sunscreen with a unique patent for stabilizing avobenzone (UVA sunscreen) for over eight hours. With the addition of Kintari’s new Hand & Body lotion, Kintari will continue its brand expansion across the United States and later this year into Canada, all driven by our exceptional distributors representing Kintari products.

Skinvisible Inc., is a science-based research and development company with a patented skin delivery technology Invisicare®, the foundation to every topical prescription (Rx), over-the-counter (OTC) and cosmeceutical product developed by Skinvisible. Skinvisible continues to build its worldwide patent portfolio while seeking licensees for its prescription line of dermatology focused products, while its wholly-owned subsidiary Kintari focuses exclusively on the marketing of OTC and cosmeceutical products. The Company has sixteen patents worldwide and a portfolio of over forty products ready to be licensed to the marketplace.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com, www.invisicare.com

Forward-Looking Statements:This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending October 30, 2015).

John Pentony is a consultant to Skinvisible and is currently being paid nineteen hundred dollars for a program that covers the Company through January 18, 2017. There are no shares, warrants or other equity related compensation. Mr. Pentony previously represented Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock.

Skinvisible's primary objective is to license these prescription and over-the-counter products into the $65 billion global dermatology market and other medical markets. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products.

No widgets!

Add widgets to this sidebar in the Widgets panel under Appearance in the WordPress Admin.

DISCLOSURE: John Pentony is a consultant to Skinvisible and is currently being paid nineteen hundred dollars for a program that covers the Company through January 18, 2017. There are no shares, warrants or other equity related compensation. Mr. Pentony previously represented Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock.